Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Rhea-AI Summary
Stonegate Capital Partners has initiated coverage on Incannex Healthcare Inc. (NASDAQ: IXHL), a company focused on developing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics. The key highlights of the coverage include:
1. Incannex is currently conducting an FDA phase 2/3 trial for IHL-42X, targeting the treatment of Obstructive Sleep Apnea (OSA).
2. The company expects to release top-line data from the pivotal phase 2 trial of IHL-42X in the first half of 2025.
This coverage initiation by Stonegate Capital Partners suggests increased attention on Incannex's innovative therapeutic approaches and ongoing clinical trials in the cannabinoid and psychedelic-assisted treatment space.
Positive
- Stonegate Capital Partners initiates coverage, potentially increasing visibility for IXHL
- Ongoing FDA phase 2/3 trial for IHL-42X in treating Obstructive Sleep Apnea
- Pivotal phase 2 top-line data for IHL-42X expected in first half 2025
Negative
- None.
News Market Reaction – IXHL
On the day this news was published, IXHL gained 0.62%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL)
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics
- Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA)
- IHL-42X pivotal phase 2 top-line data expected first half 2025
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225397
FAQ
What is the focus of Incannex Healthcare Inc. (IXHL)?
What clinical trial is Incannex Healthcare (IXHL) currently conducting?
When does Incannex Healthcare (IXHL) expect to release top-line data for the IHL-42X trial?
Which firm initiated coverage on Incannex Healthcare (IXHL) in October 2024?
